Abstract: Bacterial resistance towards the existing class of antibacterial drugs continues to increase, posing a significant threat to the clinical usefulness of these drugs. These increasing and alarming rates of antibacterial resistance development and the decline in the number of new antibacterial drugs' approval continue to serve as a major impetus for research into the discovery and development of new antibacterial agents. We synthesized a series of D-/L-alaninyl substituted triazolyl oxazolidinone derivatives and evaluated their antibacterial activity against selected standard Gram-positive and Gram-negative bacterial strains. Overall, the compounds showed moderate to strong antibacterial activity. Compounds 9d and 10d (D-and L-alaninyl derivatives bearing the 3,5-dinitrobenzoyl substituent), 10e (L-alaninyl derivative bearing the 5-nitrofurancarbonyl group) and 9f and 10f (D-and L-alaninyl derivatives bearing the 5-nitrothiophene carbonyl moiety) demonstrated antibacterial activity (MIC: 2 µg/mL) against Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis and Moraxella catarrhalis standard bacterial strains. No significant differences were noticeable between the antibacterial activity of the D-and L-alaninyl derivatives as a result of the stereochemistry of the compounds.
Introduction
Antibacterial agents are among the successful class of drugs that are effective in treating human infectious diseases with positive clinical outcomes. However, a persistent and significant clinical problem in the fight against bacterial infections is the ever-increasing emergence of bacterial resistance to major classes of antibacterial agents [1] [2] [3] . Multiply-resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), methicillin-resistant Staphylococcus epidermidis (MRSE), vancomycin-resistant enterococci (VRE) and multidrug-resistant Mycobacterium tuberculosis (MDR-TB) are among the troublesome pathogens within the healthcare and some community settings worldwide [4] [5] [6] [7] . The emergence of antibacterial resistance continues to serve as the impetus for research into novel antibacterial drug discovery and development of more potent and safer antibacterial agents.
Oxazolidinones exemplified by linezolid (1, Figure 1 ) and more recently tedizolid phosphate (2a, Figure 1 ), which is a pro-drug of the active form tedizolid (2b, Figure 1 ), represent derivatives of this class of compounds with potent activity against multidrug-resistant Gram-positive pathogenic bacterial strains [8] [9] [10] . Linezolid is characterized by excellent oral bioavailability, tissue and organ 
Materials and Methods.

Characterization
Purification of compounds was performed with silica gel column chromatography using silica gel (Kieselgel 60, 70-230 mesh; Merck, (formerly Sigma-Aldrich), Germany, and TLC was conducted on 0.25-mm pre-coated silica gel plates (60F254, Merck). Melting points were determined on a Stuart Scientific melting point apparatus (SMP1) (Stuart, Stone, UK) and were uncorrected. Mass spectra were recorded on a Thermo Scientific DFS Gas Chromatography/Mass Spectrometer (DFS GC-MS) (Thermo Fisher Scientific, Bremen, Germany) and Waters QToF high resolution/Mass Spectrometer (LC MS/MS high resolution) (Waters Corporation, Milford, MA, USA). The 1 H-NMR and 13 C-NMR spectra in DMSO-d6 using solvent peaks as reference signals were recorded on Bruker DPX 400 MHz and Bruker Avance II 600 NMR spectrometers. Chemical shifts of protons and carbons were reported Studies from our laboratory and those of others have reported the synthesis of several triazolylmethyl oxazolidinones containing acyl or aroyl-substituted piperazine of the general structures of 5-8 ( Figure 1 ) with potent activity that is comparable or superior to linezolid against Gram-positive bacterial strains including MRSA, VRE, PRSP and MDR-TB [18, [21] [22] [23] [24] [25] [26] [27] . Moreover, other studies have also demonstrated that the incorporation of N-substituted-glycinyl moieties on the 4-N-piperazine position resulted in oxazolidinone derivatives that would fit a potential pocket identified at the bacterial ribosomal receptor binding site [27] . The most potent oxazolidinones in the glycinyl series contain the N-nitroaroyl substituents on the glycine nitrogen [23] ; in particular, the 3,5-dinitrobenzoyl and the 5-nitrofuroyl derivatives demonstrated MIC values in the range of 0.06-16 µg/mL against Gram-positive bacterial clinical isolates. On the basis of the potent antibacterial activities of the N-substituted glycinyl-triazolyl oxazolidinones, we decided to investigate the effects of incorporating D-and L-alanine as spacers instead of the glycine on the antibacterial activity with focus on the nitro-and amino-substituted aroyl and heteroaroyl derivatives. We hereby report the synthesis and qualitative structure-antibacterial activity relationships of new N-substituted-D-and L-alaninyl-triazolyl oxazolidinone derivatives of the general structures 9a-l and 10a-l, respectively.
Materials and Methods.
Characterization
Purification of compounds was performed with silica gel column chromatography using silica gel (Kieselgel 60, 70-230 mesh; Merck, (formerly Sigma-Aldrich), Germany, and TLC was conducted on 0.25-mm pre-coated silica gel plates (60F 254 , Merck). Melting points were determined on a Stuart Scientific melting point apparatus (SMP1) (Stuart, Stone, UK) and were uncorrected. Mass spectra were recorded on a Thermo Scientific DFS Gas Chromatography/Mass Spectrometer (DFS GC-MS) (Thermo Fisher Scientific, Bremen, Germany) and Waters QToF high resolution/Mass Spectrometer (LC MS/MS high resolution) (Waters Corporation, Milford, MA, USA). The 1 H-NMR and 13 C-NMR spectra in DMSO-d 6 using solvent peaks as reference signals were recorded on Bruker DPX 400 MHz and Bruker Avance II 600 NMR spectrometers. Chemical shifts of protons and carbons were reported in parts per million (ppm) downfield and upfield from solvent DMSO-d 6 (δ = 2.5; 39.7) peaks as references. Infrared (IR) spectra of solids (KBr) were recorded on an FT-IR (Jasco FT/IR-6300) (JASCO, Tokyo, Japan) spectrometer. The Elemental analyses were performed on an Elementar Vario Micro Cube CHN Analyzer (Elementar, Langenselbold, Germany). Elemental analyses (C, H, N) were used to confirm the purity of all newly synthesized compounds (>95%) and indicated by the symbols of the elements within ±0.40% of the theoretical values. Analyses were performed by The General Facilities Science (GF-S), Faculty of Science, Kuwait University, Kuwait. A solution of (tert-butoxycarbonyl)-D-alanine (1.027 gm, 5.430 mmol) in anhydrous DCM (35 mL) was treated with N, N'-dicyclohexylcarbodiimide (1.40 gm, 6.787 mmol) and 1-hydroxybenzotriazole (0.917 gm, 6.787 mmol), and the mixture was stirred under a nitrogen atmosphere for 2 h. The reaction mixture was filtered directly into a solution of the trifluoro acetate salt, 14 (2.50 gm, 5.430 mmol) and TEA (2.19 mL, 15.747 mmol) in anhydrous CH 3 CN (40 mL) at 0 • C. The reaction mixture was stirred overnight and concentrated on a rotavap under vacuum to give a viscous oil, which was dissolved in DCM (40 mL), and the precipitated urea was filtered off. The DCM layer was washed with water, 10% Na 2 CO 3 solution, brine, dried (Na 2 SO 4 ), filtered and concentrated under vacuum to give a brown foam, which was triturated with ether to yield a cream-colored crude solid. This solid was recrystallized from ethyl acetate to afford the carbamate 15a as an off-white solid, 2.07 gm, yield: 74%; mp.: 214-216 • C. 1 A solution of 15a (6.07 g, 11.73 mmol) in DCM (12.0 mL) was treated with trifluoroacetic acid (12.0 mL) and stirred to room temperature overnight. The reaction mixture was concentrated to dryness to give a brown oil, which was digested several times with ether and treated with THF/diethyl ether (1:1 mixture) with stirring to give 16a as a cream-colored solid, 4.92 g, yield: 79%. This solid was utilized for subsequent reactions without further purification. 1 
Syntheses
Preparation of (R)-5-((1H
-
Preparation of (
Compound 16b was prepared via a similar procedure to the D-alaninyl isomer 16a from (tert-butoxycarbonyl)-L-alanine (0.410 gm, 2.172 mmol), N,N -dicyclohexyl carbodiimide (0.560 gm, 2.715 mmol), 1-hydroxy -benzotriazole (0.366 gm, 2.715 mmol), TFA salt (1.00 gm, 2.172 mmol) and TEA (0.877 mL, 6.30 mmol) in a mixture of DCM (40 mL) and acetonitrile (15 mL) 
Preparation of
To an ice-cooled solution of 16a (0.700 g, 1.317 mmol) in anhyd. CH 3 CN (20 mL) was added TEA (0.70 mL) and 2-nitrobenzoyl chloride (0.363 g, 1.97 mmol), and the reaction mixture was stirred overnight. The reaction mixture was diluted with DCM (100 mL), washed with water (3 × 80 mL), 10% NaHCO 3 solution (80 mL), water (80 mL) and brine (80 mL), dried (Na 2 SO 4 ), filtered and concentrated to give a yellow solid, which was triturated with ether and filtered to give a yellow solid, 0.580 g, recrystallized (CH 3 
Compound 10a was prepared via a similar procedure to 9a from 16b (0. 
Compound 9b was prepared via a similar procedure to 9a from 16a (0.700 g, 1.317 mmol) and 3-nitrobenzoyl chloride (0.363 g, 1.97 mmol) to give a yellow solid, 0.580 g, yield: 68%; recrystallized (CH 3 
Compound 10b was prepared via a similar procedure to 9a from 16b (0.90 g, 1.693 mmol) and 
Preparation of N-((R)-1-(4-(4-((
Compound 9c was prepared via a similar procedure to 9a from 16a (0.700 g, 1.317 mmol) and 4-nitrobenzoyl chloride to give a yellow solid, 300 mg, yield: 38%, recrystallized (CH 3 
Preparation of
Compound 10c was prepared via a similar procedure to 9a from 16b (0.90 g, 1.693 mmol) and 4-nitrobenzoyl chloride (0.471 g, 2.54 mmol) to afford a yellow solid, 450 mg, yield: 47%, recrystallized (CH 3 
Compound 9d was prepared via a similar procedure to 9a from 16a (1.00 g, 1.881 mmol) and 3,5-dinitrobenzoyl chloride (0.65 g, 2.82 mmol) to give a yellow solid, 390 mg, yield: 32%, purified by silica gel column chromatography (EtOAc-Hex 10-1, EtOAc and EtOAc- 
Preparation of N-((S)-1-(4-(4-((
Compound 10d was prepared via a similar procedure to 9a from 16b (0.700 g, 1.317 mmol) and 3,5-dinitro benzoyl chloride (0.455 g, 1.976 mmol) to give a yellow solid, 382 mg, yield: 45%, recrystallization (CH 3 
Preparation of
To a stirred solution of 5-nitrofuran-2-carboxylic acid (1.77 gm, 11.288 mmol) in anhyd. DCM (30 mL) cooled in an ice bath was added oxalyl chloride (2.46 mL, 28.22 mmol) under nitrogen followed by 2 drops of dry DMF, and effervescence ensued. The ice bath was removed, and the reaction mixture was stirred 2 h. The mixture was evaporated to dryness on a rotavap to give the acid chloride as a yellow semisolid, which was dried under vacuum. The resulting acid chloride was dissolved in anhyd. DCM (30 mL) and added in rapid drops to a solution of the TFA salt 16a (1.5 g, 2.822 mmol) and TEA (2.14 mL, 11.288 mmol) in CH 3 CN (32 mL) with cooling in an ice bath. The reaction mixture was left to stir to room temperature overnight under nitrogen and concentrated to dryness. The residue was dissolved in DCM and washed with water, 10% Na 2 CO 3 solution, water, brine and dried with Na 2 SO 4 , filtered and concentrated to give a brown foam, which was triturated with ether and hexane 
Compound 10e was prepared via a similar procedure to 9e from 16b (0.700 g, 1.317 mmol) and 5-nitrofuran-2-carboxylic acid (0.827 g, 5.268mmol) to give a yellowish-brown solid, 356 mg, yield 46%, recrystallized (CH 3 169.8, 159.1, 155.4, 153.8, 153.5, 153.1, 145.8, 135.4 135.3, 133.4, 133.3, 133.3, 130.2, 128, 125.9, 119.8, 114.3 
Preparation of N-((S)-1-(4-(4-((R)-(5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl) piperazin-1-yl)-1-oxopropan-2-yl)-2-nitrobenzene sulfonamide 10g
Compound 10g was prepared via a similar procedure to 9a from 16b (700 mg, 1.317 mmol) and 2-nitrobenzenesulfonyl chloride (4-6 mg, 1.834 mmol), to give a yellow solid, 265 mg, yield 30%, recrystallized (CH 3 CN), mp.: 78-80 • C. 1 
Preparation of N-((R)-1-(4-(4-((R)-5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl) piperazin-1-yl)-1-oxopropan-2-yl)-3-nitrobenzenesulfonamide 9h
Compound 9h was prepared via a similar procedure to 9a from 16a (660 mg, 1.241 mmol) and 3-nitrobenzenesulfonyl chloride (412 mg, 1.862 mmol) to give a yellow solid, which was triturated with ether and filtered to give a yellow solid, 300 mg, 40% yield, recrystallized (CH 3 CN) 
Preparation of N-((S)-1-(4-(4-((R)-5-((
Compound 10h was prepared via a similar procedure to 9a from 16b (700 mg, 1.317 mmol) and 3-nitrobenzenesulfonyl chloride (437 mg, 1.975 mmol) to give a yellow solid, 180 mg, yield 23%, recrystallized (EtOAc); mp.: 108-110 • C. 1 Compound 10l was prepared via a similar procedure to 9a from 16b (700 mg, 1.317 mmol) and 4- 1H-1,2,3-triazol-1-yl) 
Preparation of N-((R)-1-(4-(4-((R)-5-((1H
Preparation of N-((R)-1-(4-(4-((R)-5-((
An ice cooled solution of 2-((tert-butoxycarbonyl) amino-benzoic acid (0.446 gm, 1.881 mmol) in anhyd. DCM (40 mL) was treated with N, N -dicyclohexylcarbodiimide (485 mg, 2.351 mmol) and 1-hydroxybenzotriazole (318 mg, 6.787 mmol), respectively, and the reaction mixture was stirred for 2 h under nitrogen. The reaction mixture was then filtered into a solution of the TFA salt 16a (1.00 g, 1.881 mmol) and TEA (0.760 mL, 5.45 mmol) in anhyd. CH 3 CN (15 mL) and left stirring at room temperature overnight. The reaction mixture was concentrated to give a crude brown oil, which was dissolved in DCM, washed with water, 10% Na 2 CO 3 solution, brine, dried Na 2 SO 4 
Antibacterial Susceptibility Testing
Antibacterial susceptibility testing was performed by determining the minimum inhibitory concentrations (MIC, µg/mL), which is defined as the lowest concentration of a compound that inhibits visible bacterial growth. The MIC was determined on Mueller-Hinton (MH) agar with medium containing dilutions of antibacterial agents ranging from 0.12-32 µg/mL. Linezolid [24, 28] , used as the reference standard antibacterial agent, was dissolved in 60% ethanol in water and test compounds in 80% DMSO in water. The antibacterial activity of the compounds was evaluated against 6 standard reference Gram-positive and Gram-negative bacterial strains available at the MRSA Reference Laboratory, Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait. The Gram-positive standard bacterial strains used in this study consisted of S. aureus ATCC 25923, S. epidermidis ATCC 12228 and E. faecalis ATCC 29212, and the Gram-negative bacterial strains included E. coli ATCC 25922, H. influenzae ATCC 49247 and M. catarrhalis ATCC 8176. MH agar plates were used for all staphylococci and enterococci, while the MH agar plates were supplemented with 5% sheep blood to facilitate the growth of S. pneumoniae, H. influenzae and M. catarrhalis. For all, the final bacterial concentration for inocula was 10 7 CFU/mL, incubated at 35 • C for 18 h.
Results and Discussion
Chemistry
The final compounds, (D)-alaninyl isomers 9a-l and the (L)-alaninyl isomers 10a-l, were synthesized as outlined in Scheme 1 according to reported literature procedures starting from commercially available piperazine 11 and 3,4-difluoronitrobenzene 12 [18, 23, 28] 
Antibacterial Evaluation
A total of twenty-four final compounds comprised of the (D)-alaninyl 9a-l and (L)-alaninyl 10a-l oxazolidinone derivatives containing nitro-and amino-aroyl substitutions and two tertbutoxycarbonyl intermediate compounds (15a and 15b) were evaluated for their antibacterial activity against standard Gram-positive and Gram-negative bacterial strains. The Gram-positive standard bacterial strains used in this study consisted of S. aureus ATCC 25923, S. epidermidis ATCC 12228 and E. faecalis ATCC 29212, while the Gram-negative bacterial strains included Escherichia coli ATCC 25922, Haemophilus influenzae ATCC 49247 and Moraxella catarrhalis ATCC 8176. Antibacterial susceptibility testing was carried out using the agar dilution method on Mueller-Hinton (MH) agar according to the Clinical and Laboratory Standard Institute (CSLI) [29] , and the data are presented in Table 1 . With a minimum inhibitory concentration of >32 µg/mL, none of the compounds demonstrated acceptable antibacterial activity against the Gram-negative bacterial strains, namely E. coli ATCC 25922 and H. influenzae ATCC 49247. Overall, the novel (D)-alaninyl and (L)-alaninyl oxazolidinones showed moderate to strong antibacterial activity against the Gram-positive bacterial strains tested with a MIC range of 2->16 µg/mL. In general, there is no identifiable significant difference between the antibacterial activity of the (D)-alaninyl and (L)-alaninyl oxazolidinone derivatives, suggesting similar binding interaction at the ribosomal receptor binding site irrespective of the stereochemistry at the alaninyl side-chain spacer. However, in some of the derivatives, the (L)-alaninyl spacer seemed to have a slightly improved antibacterial activity; for example, the 4-nitrobenzoyl (D)-alaninyl oxazolidinone derivative 9c (MIC: 8 and 4 µg/mL) was 1-3-fold less active than the corresponding (L)-alaninyl derivative 10c (MIC: 2 and 2 µg/mL) against S. epidermidis ATCC 12228 and E. faecalis ATCC 29212, respectively. Similarly, the 5-nitrofuran-2-carbonyl substituted (L)-alaninyl oxazolidinone derivative 10e (MIC: 2 and 2 µg/mL) demonstrated 1-3-fold superior antibacterial activity to the corresponding (D)-alaninyl oxazolidinone derivative 9e (MIC: 8 and 4 µg/mL), against S. aureus ATCC 25923 and E. faecalis ATCC 29212, respectively. Overall, aminoaryl, nitroaroyl and nitroheteroaroyl substitutions in the (D/L)-alaninyl oxazolidinone derivatives favored 
A total of twenty-four final compounds comprised of the (D)-alaninyl 9a-l and (L)-alaninyl 10a-l oxazolidinone derivatives containing nitro-and amino-aroyl substitutions and two tert-butoxycarbonyl intermediate compounds (15a and 15b) were evaluated for their antibacterial activity against standard Gram-positive and Gram-negative bacterial strains. The Gram-positive standard bacterial strains used in this study consisted of S. aureus ATCC 25923, S. epidermidis ATCC 12228 and E. faecalis ATCC 29212, while the Gram-negative bacterial strains included Escherichia coli ATCC 25922, Haemophilus influenzae ATCC 49247 and Moraxella catarrhalis ATCC 8176. Antibacterial susceptibility testing was carried out using the agar dilution method on Mueller-Hinton (MH) agar according to the Clinical and Laboratory Standard Institute (CSLI) [29] , and the data are presented in Table 1 . With a minimum inhibitory concentration of >32 µg/mL, none of the compounds demonstrated acceptable antibacterial activity against the Gram-negative bacterial strains, namely E. coli ATCC 25922 and H. influenzae ATCC 49247. Overall, the novel (D)-alaninyl and (L)-alaninyl oxazolidinones showed moderate to strong antibacterial activity against the Gram-positive bacterial strains tested with a MIC range of 2->16 µg/mL. In general, there is no identifiable significant difference between the antibacterial activity of the (D)-alaninyl and (L)-alaninyl oxazolidinone derivatives, suggesting similar binding interaction at the ribosomal receptor binding site irrespective of the stereochemistry at the alaninyl side-chain spacer. However, in some of the derivatives, the (L)-alaninyl spacer seemed to have a slightly improved antibacterial activity; for example, the 4-nitrobenzoyl (D)-alaninyl oxazolidinone derivative 9c (MIC: 8 and 4 µg/mL) was 1-3-fold less active than the corresponding (L)-alaninyl derivative 10c (MIC: 2 and 2 µg/mL) against S. epidermidis ATCC 12228 and E. faecalis ATCC 29212, respectively. Similarly, the 5-nitrofuran-2-carbonyl substituted (L)-alaninyl oxazolidinone derivative 10e (MIC: 2 and 2 µg/mL) demonstrated 1-3-fold superior antibacterial activity to the corresponding (D)-alaninyl oxazolidinone derivative 9e (MIC: 8 and 4 µg/mL), against S. aureus ATCC 25923 and E. faecalis ATCC 29212, respectively. Overall, aminoaryl, nitroaroyl and nitroheteroaroyl substitutions in the (D/L)-alaninyl oxazolidinone derivatives favored retention of antibacterial activity and showed selective activity against S. epidermidis ATCC 12228 and E. faecalis ATCC 29212. The precise reasons for this are unknown. However, the presence of these moieties might result in additional interactions at the ribosomal receptor binding sites, due to a combination of H-bond acceptor and/or donor groups coupled with potential van der Waals interactions [15, 27] . In addition, the observed selective activity against S. epidermidis ATCC 12228 and E. faecalis ATCC 29212 could also suggest a subtle difference in the conformation of rRNA nucleotides in these two bacterial strains, which may have some effect on the interaction with the compounds. Conformation changes of rRNA nucleotide had been utilized to explain dramatic differences in the interactions for some antibiotics, namely macrolides and lincosamides, respectively [14, 30] . The nitro-substituted derivatives showed improved activity against the Gram-negative respiratory pathogen M. catarrhalis ATCC 25922 with an MIC range of 2-8 µg/mL. In addition, previous studies from our laboratory and others have shown that incorporation of 5-nitro-2-furoyl and 3,5-dinitrobenzoyl moieties selectively enhanced antibacterial activity of N-substituted-piperazinyl oxazolidinone derivatives [27, 31] . However, we anticipated that the incorporation of the alanine spacer group may result in potential hydrogen bond acceptor and donor interactions in addition to hydrophobic interaction due to the presence of the aroyl, heteroaroyl and methyl moieties, whose orientation at the ribosomal receptor binding site may result in favorable stereochemistry that might positively influence the observed antibacterial activity. Moreover, the 5-nitrofuran-2-carbonyl (D/L)-alaninyl oxazolidinone derivatives were less active than the previously reported 5-nitrofuran-2-carbonyl glycinyl oxazolidinone derivatives with demonstrated potent antibacterial activity, with MIC value ranges of 2-8 and 0.06-0.50 µg/mL [23] , respectively. The findings from the present study further suggest that the glycinyl spacer probably favors or permits a more effective interaction of the compounds at the bacterial ribosomal receptor binding site [27] , which eventually translates into more potent antibacterial activity [23] . Furthermore, previous studies from our laboratory and others have demonstrated that unsubstituted-benzenesulfonyl and tolylsulfonyl groups generally resulted in oxazolidinone derivatives with reduced antibacterial activity compared with the benzoyl and substituted-benzoyl derivatives [26, 27, 31] . Therefore, data from the present study further elaborate that the introduction of the electron withdrawing nitro group alone does not significantly improve antibacterial activity. This is evident from the fact that the nitrobenzenesulfonyl (D/L)-alaninyl oxazolidinone derivatives were also generally less active than the corresponding nitrobenzoyl derivatives with an MIC value range of 2->16 µg/mL. retention of antibacterial activity and showed selective activity against S. epidermidis ATCC 12228 and E. faecalis ATCC 29212. The precise reasons for this are unknown. However, the presence of these moieties might result in additional interactions at the ribosomal receptor binding sites, due to a combination of H-bond acceptor and/or donor groups coupled with potential van der Waals interactions [15, 27] . In addition, the observed selective activity against S. epidermidis ATCC 12228 and E. faecalis ATCC 29212 could also suggest a subtle difference in the conformation of rRNA nucleotides in these two bacterial strains, which may have some effect on the interaction with the compounds. Conformation changes of rRNA nucleotide had been utilized to explain dramatic differences in the interactions for some antibiotics, namely macrolides and lincosamides, respectively [14, 30] . The nitrosubstituted derivatives showed improved activity against the Gram-negative respiratory pathogen M. catarrhalis ATCC 25922 with an MIC range of 2-8 µg/mL. In addition, previous studies from our laboratory and others have shown that incorporation of 5-nitro-2-furoyl and 3,5-dinitrobenzoyl moieties selectively enhanced antibacterial activity of N-substituted-piperazinyl oxazolidinone derivatives [27, 31] . However, we anticipated that the incorporation of the alanine spacer group may result in potential hydrogen bond acceptor and donor interactions in addition to hydrophobic interaction due to the presence of the aroyl, heteroaroyl and methyl moieties, whose orientation at the ribosomal receptor binding site may result in favorable stereochemistry that might positively influence the observed antibacterial activity. Moreover, the 5-nitrofuran-2-carbonyl (D/L)-alaninyl oxazolidinone derivatives were less active than the previously reported 5-nitrofuran-2-carbonyl glycinyl oxazolidinone derivatives with demonstrated potent antibacterial activity, with MIC value ranges of 2-8 and 0.06-0.50 µg/mL [23] , respectively. The findings from the present study further suggest that the glycinyl spacer probably favors or permits a more effective interaction of the compounds at the bacterial ribosomal receptor binding site [27] , which eventually translates into more potent antibacterial activity [23] . Furthermore, previous studies from our laboratory and others have demonstrated that unsubstituted-benzenesulfonyl and tolylsulfonyl groups generally resulted in oxazolidinone derivatives with reduced antibacterial activity compared with the benzoyl and substituted-benzoyl derivatives [26, 27, 31] . Therefore, data from the present study further elaborate that the introduction of the electron withdrawing nitro group alone does not significantly improve antibacterial activity. This is evident from the fact that the nitrobenzenesulfonyl (D/L)-alaninyl oxazolidinone derivatives were also generally less active than the corresponding nitrobenzoyl derivatives with an MIC value range of 2->16 µg/mL. 
